Figure S1. The effect of evogliptin on Nrf2/HO-1 expression.

(**A**) Primary hepatocyte was pretreated with LPS for 2h, and then exposed to evogliptin for 24 h. The expression of Nrf2 and HO-1 analyzed by western blot. Data represented in the bar graph are the mean ± SEM of three independent measurements. **P < 0.01. (B) Primary HC transfected with Nrf2 siRNA or control (Con)-siRNA for 48 h were subjected to western blot analysis and real-time RT-PCR analysis. (C) Primary HC transfected with Nrf2 siRNA or control (Con)-siRNA for 48 h were subjected to real-time RT-PCR analysis using primers specific for Nrf2, HO-1, iNOS, IL1α, IL1β and IL6. *P < 0.05, **P < 0.01.

Figure S2. The inhibitory effect of evogliptin on hepatic stellate cell activation.

(**A**) Primary hepatic stellate cells morphology was analyzed using microscopy. Primary HSCs were cultured for 2 h, after which unattached cells and debris were removed by washing. HSCs were further cultured for three, five, and 7 days in DMEM containing 0.5% FBS with or without evogliptin. (**B,C**) Western blot analysis of SMA, collagen and CTGF expression in cultured HSCs. Data in the graph are represented as the mean ± SEM. *$P<0.05$, **$P<0.01$ relative to the 1 day. [#]$P<0.05$ relative to the 7 days.